Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. MGRX
stocks logo

MGRX

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
AI Stock Picker
AI Stock Picker

Valuation Metrics

The current forward P/E ratio for Mangoceuticals Inc (MGRX.O) is 0.00, compared to its 5-year average forward P/E of 0.00. For a more detailed relative valuation and DCF analysis to assess Mangoceuticals Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
0.00
Current PE
0.00
Overvalued PE
0.00
Undervalued PE
0.00

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
0.00
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.00
Undervalued EV/EBITDA
0.00

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
0.00
Current PS
0.00
Overvalued PS
0.00
Undervalued PS
0.00
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Intellectia AI SwingMax
Intellectia AI SwingMax

MGRX News & Events

Events Timeline

(ET)
2025-11-13
14:33:09
Novo refutes collaboration with Mangoceuticals regarding obesity medication, according to Reuters.
select
link
2025-11-13
14:28:41
Eli Lilly Declares No Connection to Mangoceuticals
select
link
2025-11-13
07:24:32
Mangoceuticals Collaborates with Eli Lilly and Novo to Offer Zepbound and Wegovy Access
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
5.0
11-14Benzinga
Novo Nordisk, the Manufacturer of Ozempic, Encounters Board Restructuring

  • Mikael Dolsten Withdraws Candidacy: Novo Nordisk board director Mikael Dolsten will not seek election to the Board of Directors due to personal circumstances, and the Novo Nordisk Foundation will not propose a replacement candidate.

  • Board Overhaul and Shareholder Concerns: The Novo Nordisk Foundation aims to appoint its chair, Lars Rebien Sørensen, to lead the board amid a shareholder revolt, with mixed reactions from investors regarding governance and strategic direction.

  • Aggressive M&A Strategy: Novo Nordisk CEO Mike Doustdar is pursuing a more aggressive strategy in the obesity drug market, including a significant bid for Metsera Inc, signaling a shift towards rapid growth and competitiveness against Eli Lilly.

  • Drug Access Initiatives: Mangoceuticals launched programs providing direct access to GLP-1 medications, aligning with recent pricing agreements from the White House aimed at reducing costs for government programs and Medicare patients.

[object Object]
Preview
2.0
11-14Benzinga
RLX Technology Shares Rise 6%; Check Out 20 Stocks Making Moves in Premarket Trading

  • RLX Technology Inc Performance: RLX Technology's shares rose 6% to $2.47 in pre-market trading after reporting third-quarter earnings of 3 cents per share and $158.6 million in sales.

  • Notable Gainers: Cidara Therapeutics surged 92% to $203.50 following a significant ownership disclosure, while other companies like Binah Capital Group and Expion360 also saw substantial pre-market gains.

  • Significant Losers: TSS Inc experienced a 40.2% drop to $9.10 after reporting a year-over-year decline in financial results, with enVVeno Medical Corp and Nuvve Holding Corp also facing significant losses.

  • Market Overview: The pre-market trading session showed a mix of gains and losses among various stocks, reflecting varied financial performances and investor reactions to earnings reports.

[object Object]
Preview
2.0
11-14TipRanks
Investors Abandon Mangoceuticals Stock (MGRX) Following Rejection of Partnership by Eli Lilly and Novo Nordisk

  • Mangoceuticals Stock Decline: Shares of Mangoceuticals (MGRX) fell over 20% after Eli Lilly and Novo Nordisk denied any partnership regarding obesity drug distribution, following a previous surge in stock price based on the company's claims.

  • Legal and Market Context: The company had previously faced legal action from Eli Lilly for misleading marketing and recently settled a court injunction. The obesity medication market is highly competitive, with significant financial implications for both consumers and the healthcare industry.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Mangoceuticals Inc (MGRX) stock price today?

The current price of MGRX is 1.18 USD — it has decreased -4.07 % in the last trading day.

arrow icon

What is Mangoceuticals Inc (MGRX)'s business?

Mangoceuticals, Inc. is focused on developing men’s and women’s health and wellness products and services via a secure telemedicine platform. The Company connects consumers to licensed healthcare professionals through its Website at www.MangoRX.com, for the provision of care via telehealth on its customer portal. It has developed and is commercially marketing a brand of erectile dysfunction (ED) products under the brand name Mango, a brand of hair-loss products under the brand name Grow, a brand of hormone balance and therapy products under the name Mojo, and a brand of weight-loss products under the brand name Slim. The Mango ED product includes the three ingredients: Either Sildenafil (the active ingredient in Viagra) or Tadalafil (the active ingredient in Cialis), and Oxytocin. Mango GROW includes four ingredients: Minoxidil (the active ingredient in Rogaine) and Finasteride (the active ingredient in Propecia), Vitamin D3 and Biotin, which are available as dietary supplements.

arrow icon

What is the price predicton of MGRX Stock?

Wall Street analysts forecast MGRX stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for MGRX is  USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Mangoceuticals Inc (MGRX)'s revenue for the last quarter?

Mangoceuticals Inc revenue for the last quarter amounts to 84.25K USD, decreased -36.83 % YoY.

arrow icon

What is Mangoceuticals Inc (MGRX)'s earnings per share (EPS) for the last quarter?

Mangoceuticals Inc. EPS for the last quarter amounts to -0.69 USD, decreased -95.35 % YoY.

arrow icon

What changes have occurred in the market's expectations for Mangoceuticals Inc (MGRX)'s fundamentals?

The market is revising No Change the revenue expectations for MGRX for , with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by -46.61%.
arrow icon

How many employees does Mangoceuticals Inc (MGRX). have?

Mangoceuticals Inc (MGRX) has 0 emplpoyees as of December 05 2025.

arrow icon

What is Mangoceuticals Inc (MGRX) market cap?

Today MGRX has the market capitalization of 16.41M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free